Curadh and Alpha Fusion Advance Astatine-211 Radiopharmaceuticals Partnership

CHESTER SPRINGS, Pa., July 23, 2025 /PRNewswire/ -- Curadh MTR Inc. ("Curadh") and Alpha Fusion, Inc. ("Alpha Fusion") will present on the clinical development of radiopharmaceutical products at the upcoming 4th Targeted Radiopharmaceuticals Summit US being held later this month in San Diego. The companies recently announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211)-based radiopharmaceuticals targeting multiple cancers.

Alison Armour, Chief Medical Officer & Founder Curadh MTR will be leading a seminar titled Optimizing Clinical Design to Ensure Patient Safety in Radiopharmaceutical Development. "At the recent World Astatine Community Meeting, I presented "Why Astatine Will Be Important for The Future of Molecularly Targeted Radiopharmaceuticals," added Dr. Armour. "Astatine's short 7.2-hour half-life, offers unique benefits over other radioisotopes including significantly reduced radiation exposure to patients, caregivers and healthcare facilities personnel." 

"Alpha Fusion is currently the only company in the world with multiple At-211-based therapeutics in clinical trials, and we are excited to advance our collaboration based on the outstanding work by Dr. Watabe and the team at Alpha Fusion in Japan," added Glenn Kazo, CEO of Curadh. 

Tadashi Watabe, M.D., Ph.D., Graduate School of Medicine, University of Osaka recently presented initial results at SNMMI of a Phase I investigator-initiated clinical trial that confirmed the tolerability of At-211 and its preliminary efficacy in patients with thyroid cancer refractory to radioiodine therapy. "With the swift advancements in At-211 clinical development, we are excited to accelerate our expansion into the U.S. and global markets. This progress is made possible through our partnership, which combines Alpha Fusion's platform with Curadh's extensive expertise in radiopharmaceuticals," stated Sunao Fujioka, CEO of Alpha Fusion.

About Curadh: Curadh MTR, Inc., is dedicated to advancing second-generation radiopharmaceuticals through innovative drug design and strategic partnerships combining novel targets and new radioisotopes. Founded by Dr. Alison Armour, who led the clinical development of Pluvicto®, the world's leading radiopharmaceutical drug, Curadh is headed by an expert team in MTR development. Curadh Inquiries

About Alpha Fusion Co., Ltd.: Alpha Fusion Co., Ltd. was founded based on research results from Osaka University and the Japan Science and Technology Agency with the aim of practicalizing Astatine drug discovery. In the rapidly expanding field of Targeted Alpha Therapy, Alpha Fusion Co., Ltd. mission is to maximize the potential of Astatine therapy, transforming the lives of all patients and their families affected by cancer into ones filled with hope and understanding. Alpha Fusion Inquiries

View original content:https://www.prnewswire.com/news-releases/curadh-and-alpha-fusion-advance-astatine-211-radiopharmaceuticals-partnership-302511252.html

SOURCE Curadh MTR, Inc